Literature DB >> 21708876

Association of lipoprotein-associated phospholipase A(2) and endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA).

Parveen K Garg1, Robyn L McClelland, Nancy S Jenny, Michael Criqui, Kiang Liu, Joseph F Polak, Neal W Jorgensen, Mary Cushman.   

Abstract

Mechanisms underlying the role of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in atherosclerotic development are not completely understood. We evaluated the relationship of Lp-PLA(2) with endothelial dysfunction, an early manifestation of atherosclerosis, in a cohort without known clinical cardiovascular disease. A total of 2809 participants in the Multi-Ethnic Study of Atherosclerosis underwent plasma Lp-PLA(2) mass and activity measurement and brachial artery flow-mediated vasodilation testing. In adjusted linear regression models, higher Lp-PLA(2) mass and activity levels were not associated with lower endothelial function (-0.04%, p = 0.51 and -0.09%, p = 0.10, respectively). Among individuals with subclinical atherosclerosis based on ankle-brachial index (ABI) or carotid intima-media thickness (IMT), Lp-PLA(2) mass and activity were not associated with lower endothelial function (-0.03%, p = 0.88 and -0.31%, p = 0.16 for ABI < 1.00; 0.01%, p = 0.94 and -0.15%, p = 0.20 for abnormal carotid IMT). In summary, Lp-PLA(2) is not associated with endothelial dysfunction, suggesting its role in atherosclerosis development is primarily related to other factors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21708876     DOI: 10.1177/1358863X11411360

Source DB:  PubMed          Journal:  Vasc Med        ISSN: 1358-863X            Impact factor:   3.239


  11 in total

1.  Increased soluble vascular adhesion molecule-1 concentration is associated with impaired coronary flow reserve in cardiac syndrome X.

Authors:  Byung Ju Shim; Dong Hyeon Lee; Ho Joong Youn
Journal:  Heart Vessels       Date:  2013-10-31       Impact factor: 2.037

2.  Long-term darapladib use does not affect coronary plaque composition assessed using multimodality intravascular imaging modalities: a randomized-controlled study.

Authors:  Woong Gil Choi; Megha Prasad; Ryan Lennon; Rajiv Gulati; Abhiram Prasad; Lilach O Lerman; Amir Lerman
Journal:  Coron Artery Dis       Date:  2018-03       Impact factor: 1.439

Review 3.  Treating coronary disease and the impact of endothelial dysfunction.

Authors:  Yasushi Matsuzawa; Raviteja R Guddeti; Taek-Geun Kwon; Lilach O Lerman; Amir Lerman
Journal:  Prog Cardiovasc Dis       Date:  2014-10-22       Impact factor: 8.194

4.  Lipoprotein-Associated Phospholipase A2 is Linked with Poor Cardio-Metabolic Profile in Patients with Ischemic Stroke: A Study of Effects of Statins.

Authors:  Hayder M Alkuraishy; Ali I Al-Gareeb; Huda J Waheed
Journal:  J Neurosci Rural Pract       Date:  2018 Oct-Dec

5.  Is Lipoprotein-Associated Phospholipase A2 a Link between Inflammation and Subclinical Atherosclerosis in Rheumatoid Arthritis?

Authors:  Anna Södergren; Kjell Karp; Christine Bengtsson; Bozena Möller; Solbritt Rantapää-Dahlqvist; Solveig Wållberg-Jonsson
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411

Review 6.  Emerging families of biomarkers for coronary artery disease: inflammatory mediators.

Authors:  Josef Yayan
Journal:  Vasc Health Risk Manag       Date:  2013-07-31

7.  Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement.

Authors:  Dongdan Zheng; FanFang Zeng; Anping Cai; Huocheng Liao; Ling Liu; Ruofeng Qiu; Rulin Xu; Chun Xiao; Weiyi Mai
Journal:  Lipids Health Dis       Date:  2014-03-01       Impact factor: 3.876

8.  Endothelial Dysfunction in Children With Obstructive Sleep Apnea Is Associated With Elevated Lipoprotein-Associated Phospholipase A2 Plasma Activity Levels.

Authors:  Leila Kheirandish-Gozal; Mona F Philby; Zhuanghong Qiao; Abdelnaby Khalyfa; David Gozal
Journal:  J Am Heart Assoc       Date:  2017-02-09       Impact factor: 5.501

9.  Effects and potential mechanism of atorvastatin treatment on Lp-PLA2 in rats with dyslipidemia.

Authors:  Dongdan Zheng; Anping Cai; Rulin Xu; Zhuocheng Mai; Yingling Zhou; Fanfang Zeng; Liwen Li; Weiyi Mai
Journal:  Arch Med Sci       Date:  2017-08-10       Impact factor: 3.318

10.  Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease.

Authors:  Ani Manichaikul; Xin-Qun Wang; Li Li; Jeanette Erdmann; Guillaume Lettre; Joshua C Bis; Dawn Waterworth; Mary Cushman; Nancy S Jenny; Wendy S Post; Walter Palmas; Michael Y Tsai; Lars Wallentin; Harvey White; Heribert Schunkert; Christopher J O'Donnell; David M Herrington; Stephen S Rich; Michelle L O'Donoghue; Annabelle Rodriguez
Journal:  PLoS One       Date:  2018-10-05       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.